Michail_Petrov-96
A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB’s (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in disease activity.
In the study, DZP was given intravenously every four weeks for 48 weeks. Results showed that
